Publication | Closed Access

Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients

Hematological MalignancyKiller Immunoglobin-like ReceptorMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematologyImmunologyTyrosine Kinase InhibitorsAdult T-cell Leukemia-lymphomaImmunotherapyPharmacologyMyeloid Neoplasia